PDF(995 KB)
PDF(995 KB)
PDF(995 KB)
36株青少年幽门螺杆菌耐药分析
Antimicrobial resistance of 36 strains of Helicobacter pylori in adolescents
目的：了解该地区青少年幽门螺杆菌(HP)常用抗菌药物的耐药性。方法：对108例青少年患者进行胃镜检查，并取胃黏膜标本1块进行HP培养分离，采用Kirby-Baner药敏纸片对培养分离到的菌株进行抗菌药物的敏感性试验。结果：108例中成功分离出HP菌株36例，对克拉霉素耐药率8.3%（3/36）、阿莫西林耐药率33.3%（12/36）、甲硝唑耐药率94.4%（34/36）、呋喃唑酮耐药率16.7%（6/36），而庆大霉素和左氧氟沙星均未检出耐药菌株。结论：该地区青少年HP对甲硝唑和阿莫西林耐药率较高，对克拉霉素和呋喃唑酮耐药率较低，而对庆大霉素和左氧氟沙星无耐药菌株。［中国当代儿科杂志，2009，11（3）：210-212］
OBJECTIVE: To investigate the resistance of Helicobacter pylori (H.pylori) to antimicrobial agents in adolescents. METHODS: One hundred and eight adolescents (6-18 years old) underwent a gastroscopy examination. H.pylori strains were isolated from gastric mucosa. Antimicrobial susceptibility testing was performed by means of Kirby-Baner. RESULTS: Thirty-six H.pylori strains were identified. The resistant rate of H.pylori strains to clarithromycin, fruranzolidone and amoxicillin was 8.3%, 16.7% and 33.3%, respectively. H.pylori strains showed a high resistance to metronidazole (94.4%), while no strain was resistant to gentamicin and levofloxacin. CONCLUSIONS:The H.pylori strains from the adolescents in Zhejiang showed a high resistance to metronidazole and amoxicillin but a low resistance to clarithromycin and fruranzolidone. All of H.pylori strains were susceptive to gentamicin and levofloxacin.［Chin J Contemp Pediatr, 2009, 11 (3):210-212］
Helicobacter pylori / Susceptibility test / Resistance / Adolescent
［1］彭新平，张金定，王跃平.幽门螺杆菌感染与儿童慢性胃炎及消化性溃疡的关系（附56例分析）［J］.中国当代儿科杂志，2002，4（3）：227-228.
［2］蒲秀红，郭晓清，石玉玲，安涛，邱萌，裘晓霞，等.粪便幽门螺杆菌抗原检测对儿童复发性腹痛病因诊断的价值［J］.中国当代儿科杂志，2005， 7（5）：426-428.
［3］卢燕鸣.小儿幽门螺杆菌相关性疾病［J］.中国当代儿科杂志，2002， 4（6）：567-568.
［4］姜葵，张建中，潘国宗.幽门螺杆菌耐药性检测［J］.中国人兽共患病杂志, 2000, 16(6):76-78.
［5］Bazzoli F, Pozzato P. Therapy of H.pylori infection［J］. J Physiol Pharmacol, 1997, 48 （4 Suppl）:39-46.
［6］Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy［J］.Gastroenterology, 1992, 102(2):493-496.
［7］Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, et al. High rate of post-therapeutic resistance after failure of macrolide-nitromidazole triple therapy to cure Helicobacter pylori infection:impact of two second-line therapies in a randomized study［J］. Aliment Pharmacol Ther, 2002, 16(2):315-324.
［8］Dzierzanowska-Fangrat K, Rozynek E, Józwiak P, Celińska-Cedro D, Madalinski K, Dzierzano-wska D. Primary resistance to Clarithromycin inclinical strains of Helicobacter pylori isolated from children in Poland［J］. Int J Antimicrob Agents, 2001, 18(4):387-390.
［9］Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods［J］. Diagn Microbiol Infect Dis, 2008, 60(4):409-415.
［10］Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia,Bulgaria［J］. J Med Microbiol, 2000, 49(5):415-418.
［11］陈洁，陈飞波，余金丹，陈学军，李中跃，章许平. 幽门螺杆菌对克拉霉素、阿莫西林、甲硝唑体外耐药性和敏感性的初步分析［J］. 中华儿科杂志, 2004, 42（10）：769-771.
［12］施杰民，李伟平.幽门螺杆菌耐药性分析［J］. 医学研究杂志, 2007, 36（7）：98-100.
［13］DiCaro S, Zocco MA, Cremonini F, Candelli M, Nista EC, Bartolozzi F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori［J］. Eur J Gastroenterol Hepatol, 2002, 14(12):1309-1312.
［14］Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori［J］. Antimicrob Agents Chemother, 1996, 40(2):477-480.
［15］李和勤,李琴,刘郁明.宝鸡市儿童Hp感染的流行病学调查［J］.中国当代儿科杂志，2004，6（5）：403-404.
［16］项立，文飞球，卓卫华，唐沂.不同疗程三联药物治疗儿童出门螺杆菌感染的疗效观察［J］.中国当代儿科杂志，2007，9（3）：205-206.
